Temporary suspension of therapy or dosage reduction may be required if hematologic toxicity occurs, or discontinuation of treatment.In patients with chronic phase CML, perform CBC every 2 weeks during the first 3 months of therapy and then every 3 months (or as clinically indicated) thereafter. ...
30 months delay for litigated drugs, ANDAs, 180-day exclusivity, state laws allowing generic forms to be substituted automatically by pharmacists for brand-name drugs prescribed by physicians, so long as physicians have not specified that the prescription must be ‘‘dispensed as written’ (also ca...
You are responsible for reporting use of the co-pay card to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the co-pay card, as may be required. You should not use the co-pay card if your insurer or health ...
"I'm not against the idea; I just want to see the evidence that this is true." Gleevec, which Sawyers was instrumental in developing, turned out to be a multikinase inhibitor. The drug was designed to target ABL in chronic myeloid leukaemia, but inhibits another kinase, KIT, in ...
Feeling like you need a prescription for success on the NCLEX? Take our nursing pharmacology test banks and we’ll be your ‘study doctors’ – no co-pay required! Go to our test banks Drug Guides NEW! Individual drug guides and nursing considerations for the most common medications used ...
The insurance company reviews the prescription from your health care provider to make sure it is covered and determines the process that needs to be followed. Specialty pharmacy. You may be required to use a specialty pharmacy to get your medicine each month. The pharmacist works with your ...
Pharmacogenomics, which integrates genomics information in the drug development and prescription processes, is one example of such technologies. The potential of genomic technologies to revolutionize medicine derive from two important observations: 1) the implementation of prior technological innovations in ...
2007, Geneva/Washington, CPTech, [http://www.cptech.org/ip/health/gleevec/] Google Scholar Kazmin A, Jack A: Thailand breaks patent for Aids drug to cut costs. Financial Times. 2006, 30 November. Pugatch M: Intellectual Property and Pharmaceutical Data Exclusivity in the Context of ...
However, the high dose of IL-2 that is required for effective treatment of certain diseases is highly toxic. Major adverse effects of such therapy include vascular leak syndrome (VLS), which results in accumulation of the intravascular fluid in organs such as lung and liver with subsequent pulmo...
Methods are provided for treating HIV and cancer in a subject in need thereof by administering to the subject therapeutically effective amounts of an mTOR inhibitor. Other methods a